Earnings Ahead

EXEL - Exelixis, Inc.

19.37 0.17 0.89

Exelixis, Inc.

Exelixis, Inc.

About

Profile

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following earl


Headquarters

Alameda, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

EXEL



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Exelixis Non-GAAP EPS of $0.10 misses by $0.09, revenue of $471.92M misses by $1.47M
  • Exelixis Q3 2023 Earnings Preview
  • Exelixis gains as Cabometyx patent trial ends (update)
  • Exelixis slumps amid Cabometyx patent trial (update)
  • Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
  • Exelixis started at buy at Wainwright on targeted oncology pipeline
  • Exelixis inks licensing deal with Insilico for tumor candidate
  • Exelixis reports positive results for Cabometyx in pancreatic cancer type
  • Exelixis appoints Amy Peterson as Chief Medical Officer
  • Exelixis lead product hits main goal in Phase 3 prostate cancer trial
  • Exelixis Non-GAAP EPS of $0.31 beats by $0.09, revenue of $469.85M beats by $25.02M
  • Exelixis Q2 2023 Earnings Preview
  • Exelixis, Teva settle patent dispute over cancer drug Cabometyx
  • Exelixis sees three Farallon nominees elected to board
  • Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
  • Exelixis Non-GAAP EPS of $0.16 misses by $0.06, revenue of $408.8M misses by $13.86M
  • Exelixis Q1 2023 Earnings Preview
  • Exelixis board member resigns; Farallon gets third board seat in victory
  • Exelixis holder Farallon files definitive materials in proxy battle
  • Exelixis supports two of Farallon's board nominees as it faces proxy fight
Date Price Open High Low Vol Change
Nov 20 34.65 34.57
34.81
34.26
1.7M 0.70%
Nov 19 34.41 34.57
34.59
33.82
2.2M -0.32%
Nov 18 34.52 34.15
34.63
34.06
1.8M 0.20%
Nov 15 34.45 34.98
35.13
34.06
2.9M -1.71%
Nov 14 35.05 35.19
35.52
34.97
3.0M -0.4%
 
Nov 13 35.19 36.02
36.37
35.1
2.0M -1.84%
Nov 12 35.85 36.34
36.49
35.81
1.7M -0.94%
Nov 11 36.19 36.32
36.48
36.1
1.9M -0.17%
Nov 8 36.25 35.9
36.6
35.85
2.2M 1.26%
Nov 7 35.8 35.38
36.17
35.26
1.8M 0.82%
Nov 6 35.51 35.3
35.84
34.97
2.5M 2.13%
Nov 5 34.77 34.08
35.15
34.08
2.8M 1.40%
Nov 4 34.29 34.12
34.65
33.76
2.6M 0.50%
Nov 1 34.12 33.44
34.45
33.34
4.5M 2.77%
Oct 31 33.2 32.4
33.6
32.3
4.4M 2.34%
Oct 30 32.44 31.4
33.32
31.18
6.7M 12.91%
Oct 29 28.73 28.48
28.98
28.3
2.8M 0.81%
Oct 28 28.5 28.17
28.57
28.05
2.0M 2.26%
Oct 25 27.87 28.34
28.34
27.86
1.0M -0.85%
Oct 24 28.11 28.34
28.79
28
1.2M -0.74%
Oct 23 28.32 28.81
28.81
28.29
1.4M -1.77%
Oct 22 28.83 28.59
29.03
28.38
1.7M 0.59%
Oct 21 28.66 28.95
29.09
28.39
2.1M -0.83%
Oct 18 28.9 29.06
29.13
28.54
2.5M -0.55%
Oct 17 29.06 29.51
29.75
28.88
3.1M -0.99%
Oct 16 29.35 28.7
29.6
28.31
3.3M 2.98%
Oct 15 28.5 26.3
28.99
26.06
8.5M 8.61%
Oct 14 26.24 26.23
26.36
26.11
825K 0.04%
Oct 11 26.23 25.76
26.36
25.76
1.1M 2.02%
Oct 10 25.71 25.32
25.73
25.17
1.7M 1.10%
Oct 9 25.43 25.37
25.75
25.25
1.3M 0.16%
Oct 8 25.39 26.34
26.34
25.37
1.6M -3.5%
Oct 7 26.31 26.66
26.66
26.26
739K -1.31%
Oct 4 26.66 26.27
26.73
26.25
980K 1.60%
Oct 3 26.24 26.52
26.9
26.16
1.2M -0.98%
Oct 2 26.5 26.24
26.52
25.86
1.4M 0.76%
Oct 1 26.3 25.98
26.4
25.87
1.3M 1.35%
Sep 30 25.95 25.95
26.31
25.73
1.3M -0.04%
Sep 27 25.96 26.26
26.37
25.92
1.4M -1.07%
Sep 26 26.24 26.1
26.38
25.96
1.6M 0.69%
Sep 25 26.06 26.25
26.4
25.99
1.5M -0.84%
Sep 24 26.28 26.4
26.67
26.19
1.3M -0.3%
Sep 23 26.36 26.5
26.58
26.17
1.8M -0.23%
Sep 20 26.42 26.8
26.8
26.1
5.8M -1.53%
Sep 19 26.83 26.9
27.1
26.65
2.4M 0.04%
Sep 18 26.82 27.66
27.73
26.56
1.7M -2.83%
Sep 17 27.6 27.36
27.83
27.31
2.0M 0.47%
Sep 16 27.47 26.58
27.5
26.54
2.0M 3.82%
Sep 13 26.46 26.34
26.5
26.19
1.4M 0.57%
Sep 12 26.31 26.63
26.63
26.17
1.2M -1.2%
Sep 11 26.63 26.21
26.75
26.2
1.5M 1.22%
Sep 10 26.31 25.55
26.35
25.55
1.9M 3.14%
Sep 9 25.51 25.15
25.6
25.12
1.5M 1.43%
Sep 6 25.15 25.68
25.69
25.12
1.4M -1.64%
Sep 5 25.57 25.61
25.77
25.3
1.2M -0.16%
Sep 4 25.61 25.67
25.67
25.35
1.7M -0.85%
Sep 3 25.83 25.87
26.39
25.76
1.3M -0.77%
Aug 30 26.03 25.98
26.08
25.72
1.9M 0.04%
Aug 29 26.02 25.85
26.27
25.79
1.3M 0.77%
Aug 28 25.82 25.75
25.84
25.56
1.2M 0%